Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

Table 2

The percentage of TLR3-, TLR7-, and TLR9-positive PBMCs and lymphocytes B CD19⁺ and lymphocytes T CD3⁺, including CD4⁺ and CD8⁺, in patients with SLE (active and nonactive), compared to healthy controls.

Cell subpopulation; (% positive cells)	Patients inactive; 𝑛=14; (a)	Patients active; 𝑛=21; (b)	Healthy; 𝑛=15; (c)	Statistical significance
TLR3 in PBMC
𝑥±SD	24.01±25.06	23.35±17.18	2.58±4.97	(a)–(c) 𝑃<0.002
Range	(0.70–84.50)	(0.43–61.83)	(0.00–19.80)	(b)-(c) 𝑃<0.001
TLR9 in PBMC
𝑥±SD	33.72±31.45	36.36±32.67	1.09±0.75	(a)–(c) 𝑃<0.001
Range	(0.98–97.5)	(0.3–98.37)	(0.05–2.50)	(b)-(c) 𝑃<0.001
TLR3 in CD3
𝑥±SD	12.34±18.72	8.69±11.13	0.69±0.94	(a)–(c) 𝑃<0.002
Range	(0.13–56.09)	(0.0–39.22)	(0.00–2.79)	(b)-(c) 𝑃<0.004
TLR3 in CD4
𝑥±SD	8.27±9.59	6.51±7.05	1.56±4.32	(a)–(c) 𝑃<0.002
Range	(0.23–22.86)	(0.18–22.60)	(0.00–16.43)	(b)-(c) 𝑃<0.02
TLR3 in CD8
𝑥±SD	7.46±14.28	3.32±4.15	0.58±0.78	(a)–(c) 𝑃>0.05
Range	(0.1–32.71)	(0.01–12.3)	(0.00–2.30)	(b)-(c) 𝑃>0.05
TLR3 in CD19
𝑥±SD	3.46±3.93	3.54±2.81	0.41±0.72	(a)–(c) 𝑃<0.02
Range	(0.04–11.90)	(0.03–9.19)	(0.00–2.70)	(b)-(c) 𝑃<0.001
TLR7 in CD19
𝑥±SD	1.41±2.89	2.85±6.52	0.05±0.06	(a)–(c) 𝑃>0.05
Range	(0.00–9.80)	(0.00–24.73)	(0.00–0.20)	(b)-(c) 𝑃<0.05
TLR9 in CD3
𝑥±SD	17.78±25.68	18.95±26.46	4.39±10.15	(a)–(c) 𝑃>0.05
Range	(0.36–66.90)	(0.37–80.44)	(0.00–40.34)	(b)-(c) 𝑃<0.03
TLR9 in CD4
𝑥±SD	15.43±15.87	18.44±16.04	3.14±7.85	(a)–(c) 𝑃>0.05
Range	(1.27–34.65)	(0.04–42.96)	(0.00–30.18)	(b)-(c) 𝑃<0.02
TLR9 in CD8
𝑥±SD	12.06±17.18	7.04±7.88	1.20±2.04	(a)–(c) 𝑃>0.05
Range	(0.74–40.77)	(0.08–21.94)	(0.00–8.17)	(b)-(c) 𝑃>0.05
TLR9 in CD19
𝑥±SD	4.33±5.86	5.84±6.35	0.78±0.95	(a)–(c) 𝑃>0.05
Range	(0.10–22.00)	(0.10–26.00)	(0.00–3.00)	(b)-(c) 𝑃<0.005